Sign in3 stories
Jain's seat, effective once a Rule 14f-1 waiting period ends, follows board designation rights tied to Celularity's September 2026 financing and comes as director Diane Parks resigns.
SEC filing
The company also amended existing Trust debt, added a director, and resolved a dispute with Helena Global Investment Opportunities in a Form 8-K covering events from September 18 through September 24, 2026.
SEC filing
The company's August 5, 2026 filing confirms his departure was immediate, with no successor named in the disclosure.
SEC filing